Evidence brief
Tesamorelin: Trial context, approved indication, and limits of extrapolation
This evidence brief separates a studied, regulated clinical context from broader online claims. It does not interpret personal information or provide treatment, administration, or purchasing guidance.
Evidence maturity: established randomized-trial evidence for a specific regulated indication; not a general-purpose outcome claim.
Human evidence
The cited randomized trial examined tesamorelin in a defined HIV-associated lipodystrophy context. Findings from a defined trial population and indication should not be extended to unrelated goals, populations, or product forms.
Preclinical context
Growth-hormone-releasing-hormone biology can provide background for the research question, but mechanism alone does not determine a clinical result for an individual.
What remains unknown
This brief does not establish long-term outcomes beyond the cited context, comparative outcomes for other populations, or a protocol for an individual.
Human-evidence table
A structured reading aid, not a treatment or product decision tool.
| Evidence maturity | Human-study context | Interpretation limit |
|---|---|---|
| established randomized-trial evidence for a specific regulated indication; not a general-purpose outcome claim. | The cited randomized trial examined tesamorelin in a defined HIV-associated lipodystrophy context. Findings from a defined trial population and indication should not be extended to unrelated goals, populations, or product forms. | This brief does not establish long-term outcomes beyond the cited context, comparative outcomes for other populations, or a protocol for an individual. |
Canadian regulatory context
Health Canada’s regulatory review documents describe a specific authorized product context. Regulatory authorization for a defined indication does not constitute advice, a referral, or a conclusion about any other use or product.
Evidence timeline
- 1
Trial program: randomized studies in a defined HIV-associated lipodystrophy population
- 2
Regulatory review: product-specific evidence assessed for a defined indication
- 3
Current: unrelated claims require their own evidence and are not inferred here
Sources and maintenance
Sources are linked directly so readers can review the original material and its limitations.
- Randomized clinical trial
Primary trial context for a defined study population.
- Health Canada Summary Basis of Decision
Official product-specific regulatory review context.